Neupogen Sales Data
| Rank 70 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Neupogen U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 70 ( 5) |
$229,912 | -2.70% | 147 | -5.77% |
| Q3 2013 | 65 ( 2) |
$236,284 | 1.60% | 156 | -4.88% |
| Q2 2013 | 67 (4) |
$232,559 | -3.07% | 164 | 0.61% |
| Q1 2013 | 63 (4) |
$239,937 | 3.86% | 163 | -4.12% |
| Q4 2012 | 67 (7) |
$231,017 | -7.01% | 170 | -3.95% |
| Q3 2012 | 60 (2) |
$248,423 | 2.65% | 177 | n/a |
| Q2 2012 | 62 (8) |
$242,012 | 1.50% | 177 | 4.12% |
| Q1 2012 | 70 | $238,427 | 0.06% | 170 | -2.86% |
| Q4 2011 | 70 (5) |
$238,289 | 0.16% | 175 | 10.76% |
| Q3 2011 | 65 (5) |
$237,915 | 0.69% | 158 | 0.64% |
| Q2 2011 | 70 (4) |
$236,294 | 2.51% | 157 | 0.64% |
| Q1 2011 | 74 | $230,515 | n/a | 156 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.